E-6201

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameE-6201
Drug Alias NameE-6201
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsDual specificity mitogen-activated protein kinase kinase inhibitorsMitogen activated protein kinase kinase kinase 1 inhibitors
TargetsTyrosine-protein kinase receptor FLT3Dual specificity mitogen-activated protein kinase kinaseMitogen activated protein kinase kinase kinase 1
Therapy Area/IndicationsPlaque psoriasisBrain metastasesSolid tumours +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJs Innopharm LtdMayo ClinicJS InnoPharm (Shanghai) Ltd
Inactive CompaniesSpirita Oncology LlcEisai LtdEisai Inc
Active IndicationsBrain metastasesSolid tumoursMelanoma
Inactive IndicationsPlaque psoriasisPsoriasisMyelodysplastic Syndromes +[5] 

Other Information

ATC CodeN/A
Related LinksN/A